Dulac Edward J III
SEC insider (Form 3/4/5 filer). CIK 0001821530. EVP, Chief Financial Officer at Intellia Therapeutics, Inc. (NTLA). 6 reported Form 4/5 transactions since Sep 2024; latest on Jul 22, 2026. Located in CAMBRIDGE, MA.
Companies Dulac Edward J III has filed insider reports for
- Intellia Therapeutics, Inc. (NTLA): Officer, EVP, Chief Financial Officer
Dulac Edward J III
CIK: 0001821530
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Intellia Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jul 22, 2026NTLA
Intellia Therapeutics, Inc.
SaleDirect8.1K shares at avg. $11.25$91K - Jul 2, 2026NTLA
Intellia Therapeutics, Inc.
SaleDirect4.7K shares at avg. $18.00$84K - Mar 1, 2026NTLA
Intellia Therapeutics, Inc.
AwardDirect61.3K shares- - Jan 5, 2026NTLA
Intellia Therapeutics, Inc.
SaleDirect6.4K shares at avg. $9.21$59K - Jul 23, 2025NTLA
Intellia Therapeutics, Inc.
SaleDirect7.5K shares at avg. $14.02$105K - Mar 1, 2025NTLA
Intellia Therapeutics, Inc.
AwardDirect47.2K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 22, 2026 | NTLA Intellia Therapeutics, Inc. | Sale | 8,111 | $11.25 | $91,249 | Direct |
| Jul 2, 2026 | NTLA Intellia Therapeutics, Inc. | Sale | 4,677 | $18.00 | $84,186 | Direct |
| Mar 1, 2026 | NTLA Intellia Therapeutics, Inc. | Award | 61,280 | - | $0 | Direct |
| Jan 5, 2026 | NTLA Intellia Therapeutics, Inc. | Sale | 6,379 | $9.21 | $58,751 | Direct |
| Jul 23, 2025 | NTLA Intellia Therapeutics, Inc. | Sale | 7,462 | $14.02 | $104,617 | Direct |
| Mar 1, 2025 | NTLA Intellia Therapeutics, Inc. | Award | 47,200 | - | - | Direct |
1-6 of 6 transactions